<h1>Paper Summary</h1>

<!--META_START-->

<p>Title: Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets  </p>

<p>Authors: A. Moreira, J. Masliah-Planchon, C. Callens, S. Vacher, C. Lecerf, M. Frelaut, E. Borcoman, N. Torossian, F. Ricci, S. Hescot, M.P. Sablin, P. Tresca, D. Loirat, S. Melaabi, O. Trabelsi-Grati, G. Pierron, D. Gentien, V. Bernard, A. Vincent Salomon, N. Servant, I. Bieche, C. Le Tourneau, M. Kamal  </p>

<p>DOI: https://doi.org/10.1016/j.ejca.2019.09.001  </p>

<p>Year: 2019  </p>

<p>Publication Type: Journal  </p>

<p>Discipline/Domain: Oncology / Precision Medicine  </p>

<p>Subdomain/Topic: Clinical actionability, molecularly targeted agents, ESCAT scale, SHIVA01 trial  </p>

<p>Eligibility: Eligible  </p>

<p>Overall Relevance Score: 75  </p>

<p>Operationalization Score: 70  </p>

<p>Contains Definition of Actionability: Yes (explicit via ESCAT framework)  </p>

<p>Contains Systematic Features/Dimensions: Yes  </p>

<p>Contains Explainability: Partial  </p>

<p>Contains Interpretability: Partial  </p>

<p>Contains Framework/Model: Yes (ESCAT)  </p>

<p>Operationalization Present: Yes  </p>

<p>Primary Methodology: Quantitative (retrospective analysis of trial data)  </p>

<p>Study Context: Retrospective classification of molecular alterations from SHIVA01 trial according to ESCAT and correlation with clinical outcomes (PFS, OS)  </p>

<p>Geographic/Institutional Context: Institut Curie, France  </p>

<p>Target Users/Stakeholders: Clinical oncologists, precision medicine researchers, trial designers  </p>

<p>Primary Contribution Type: Empirical evaluation of actionability framework (ESCAT) applied to existing trial data  </p>

<p>CL: Yes  </p>

<p>CR: Yes  </p>

<p>FE: Yes  </p>

<p>TI: No  </p>

<p>EX: Partial  </p>

<p>GA: Partial  </p>

<p>Reason if Not Eligible: N/A  </p>

<!--META_END-->

<p><strong>Title:</strong>  </p>

<p>Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets</p>

<p><strong>Authors:</strong>  </p>

<p>A. Moreira et al.</p>

<p><strong>DOI:</strong>  </p>

<p>https://doi.org/10.1016/j.ejca.2019.09.001</p>

<p><strong>Year:</strong>  </p>

<p>2019</p>

<p><strong>Publication Type:</strong>  </p>

<p>Journal</p>

<p><strong>Discipline/Domain:</strong>  </p>

<p>Oncology / Precision Medicine</p>

<p><strong>Subdomain/Topic:</strong>  </p>

<p>Clinical actionability, molecularly targeted agents, ESCAT scale, SHIVA01 trial</p>

<p><strong>Contextual Background:</strong>  </p>

<p>The paper re-evaluates the SHIVA01 precision medicine trial by applying the European Society for Medical Oncology’s Scale for Clinical Actionability of molecular Targets (ESCAT) to classify molecular alterations (MAs) that guided treatment allocation. This retrospective classification aims to understand how actionability levels correlate with clinical outcomes.</p>

<p><strong>Geographic/Institutional Context:</strong>  </p>

<p>Institut Curie, France</p>

<p><strong>Target Users/Stakeholders:</strong>  </p>

<p>Oncologists, trial designers, policy-makers in precision oncology</p>

<p><strong>Primary Methodology:</strong>  </p>

<p>Quantitative retrospective analysis</p>

<p><strong>Primary Contribution Type:</strong>  </p>

<p>Empirical reassessment of trial outcomes through an actionability framework</p>

<hr />

<h2>General Summary of the Paper</h2>

<p>The SHIVA01 trial compared molecularly targeted agents (MTAs) selected by a treatment algorithm based on tumour molecular profiling versus conventional therapy in patients with refractory metastatic solid tumours. It found no significant PFS benefit. This study retrospectively classifies MAs from SHIVA01 according to ESCAT tiers, which grade the strength of evidence linking MAs to drug efficacy. Most MAs were tier IIIA (efficacy shown in other tumour types). Worst OS was observed for tier IIIB (alterations of a different type in known actionable genes). The analysis highlights the importance of precise alteration type and evidence strength in predicting treatment benefit.</p>

<hr />

<h2>Eligibility</h2>

<p>Eligible for inclusion: <strong>Yes</strong></p>

<hr />

<h2>How Actionability is Understood</h2>

<p>Actionability is explicitly framed through ESCAT as the degree of clinical evidence supporting the use of a targeted therapy for a given molecular alteration in a specific cancer type, graded from tier I (highest) to V (no benefit).  </p>

<blockquote>
  <p>“ESCAT… defined criteria to prioritise molecular alterations (MAs) to select anticancer drugs.” (p. 202)  </p>
</blockquote>

<blockquote>
  <p>“We… classified [MAs] according to the ESCAT by assessing the level of evidence in the literature.” (p. 203)</p>
</blockquote>

<hr />

<h2>What Makes Something Actionable</h2>

<ul>
<li><p>Supported by clinical trial evidence in the same tumour type (higher ESCAT tier)  </p></li>
<li><p>Type of alteration must match that shown to confer benefit (mutation vs amplification)  </p></li>
<li><p>Evidence from other tumour types (lower tier) less predictive  </p></li>
<li><p>Preclinical or in silico evidence can guide classification when clinical data is lacking  </p></li>
<li><p>Drug-target affinity and specificity influence actionability beyond ESCAT tier  </p></li>
</ul>

<hr />

<h2>How Actionability is Achieved / Operationalized</h2>

<ul>
<li><p><strong>Framework/Approach Name(s):</strong> ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)  </p></li>
<li><p><strong>Methods/Levers:</strong> Literature review for evidence of benefit of MA-targeted MTA  </p></li>
<li><p><strong>Operational Steps / Workflow:</strong> Identify MA → Search same-cancer evidence → If absent, search cross-cancer evidence → If absent, preclinical/in silico data → Assign ESCAT tier  </p></li>
<li><p><strong>Data &amp; Measures:</strong> PFS, OS, ESCAT tier classification, patient demographics  </p></li>
<li><p><strong>Implementation Context:</strong> Retrospective re-analysis of SHIVA01 patient data  </p></li>
</ul>

<blockquote>
  <p>“For each MA, we… searched for clinical trials… in the same tumour type… then… other tumour types… then… preclinical and in silico data… Classified as tier V if no clinically meaningful benefit was reported.” (p. 203)</p>
</blockquote>

<hr />

<h2>Dimensions and Attributes of Actionability (Authors’ Perspective)</h2>

<ul>
<li><p><strong>CL (Clarity):</strong> Yes — ESCAT tiers are explicitly defined and applied  </p></li>
<li><p><strong>CR (Contextual Relevance):</strong> Yes — Same vs other tumour type evidence distinguishes tiers  </p></li>
<li><p><strong>FE (Feasibility):</strong> Yes — Relates to whether drugs are usable in context based on evidence strength  </p></li>
<li><p><strong>TI (Timeliness):</strong> No — Not addressed directly  </p></li>
<li><p><strong>EX (Explainability):</strong> Partial — ESCAT rationale is given, but biological mechanisms less discussed  </p></li>
<li><p><strong>GA (Goal Alignment):</strong> Partial — Implicit alignment with precision oncology goals  </p></li>
<li><p><strong>Other Dimensions Named by Authors:</strong> Type of alteration specificity, drug-target affinity</p></li>
</ul>

<hr />

<h2>Theoretical or Conceptual Foundations</h2>

<ul>
<li><p>ESCAT framework (Mateo et al., 2018)  </p></li>
<li><p>Prior actionability scales (OncoKB, AMP/ASCO/CAP guidelines)  </p></li>
</ul>

<hr />

<h2>Indicators or Metrics for Actionability</h2>

<ul>
<li><p>ESCAT tier assignment (I–V)  </p></li>
<li><p>Clinical endpoints: PFS, OS stratified by tier  </p></li>
</ul>

<hr />

<h2>Barriers and Enablers to Actionability</h2>

<ul>
<li><p><strong>Barriers:</strong> Low ESCAT tier prevalence, misclassification of alteration type, lack of tumour-type-specific data, coexisting resistance mutations, variability in literature interpretation  </p></li>
<li><p><strong>Enablers:</strong> In vitro/in vivo functional validation, drug specificity, comprehensive molecular profiling</p></li>
</ul>

<hr />

<h2>Relation to Existing Literature</h2>

<p>Positions ESCAT as the latest in a series of actionability frameworks and demonstrates its application to re-interpret trial results. Highlights need to refine trial algorithms with higher-tier MAs.</p>

<hr />

<h2>Summary</h2>

<p>This paper retrospectively applies the ESCAT actionability framework to the SHIVA01 trial, showing that most targeted therapies were based on alterations with low or indirect evidence (tier IIIA). The poorest OS was linked to tier IIIB cases, underscoring the critical role of precise alteration type and tumour-specific evidence in achieving clinical benefit. The work operationalizes actionability by systematically classifying MAs through literature evidence levels, providing a model for refining precision oncology trial design.</p>

<hr />

<h2>Scores</h2>

<ul>
<li><p><strong>Overall Relevance Score:</strong> 75 — Strong conceptual clarity through ESCAT, explicit linkage of features to actionability  </p></li>
<li><p><strong>Operationalization Score:</strong> 70 — Detailed process for applying ESCAT tiers; however, not a prospective operationalization</p></li>
</ul>

<hr />

<h2>Supporting Quotes from the Paper</h2>

<ul>
<li><p>“[ESCAT] defined criteria to prioritise molecular alterations (MAs) to select anticancer drugs.” (p. 202)  </p></li>
<li><p>“Most MAs… were shown to improve outcomes in other tumour types (tier IIIA). Worst outcome… in tier IIIB…” (p. 206)  </p></li>
<li><p>“For each MA, we… searched for clinical trials… in the same tumour type… other tumour types… preclinical and in silico data…” (p. 203)  </p></li>
<li><p>“This highlights the crucial importance of the type of alteration beyond the gene and/or signalling pathway itself.” (p. 207)</p></li>
</ul>

<hr />

<h2>Actionability References to Other Papers</h2>

<ul>
<li><p>Mateo J et al., 2018 — ESCAT  </p></li>
<li><p>Chakravarty D et al., 2017 — OncoKB  </p></li>
<li><p>Li MM et al., 2017 — AMP/ASCO/CAP guidelines  </p></li>
<li><p>Meric-Bernstam F et al., 2015 — Decision support framework</p></li>
</ul>
